Ferroptosis Regulator Information
General Information of the Ferroptosis Regulator (ID: REG20027)
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
hsa-miR-144-3p
can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
Browse Drug
Long-chain-fatty-acid--CoA ligase 4 (ACSL4) [Driver]
In total 2 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis Target of This Regulator | [1] | ||||
Target for Ferroptosis | Driver | ||||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | |||
Responsed Drug | Bromelain | Investigative | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
In Vitro Model |
NCI-H508 cells | Cecum adenocarcinoma | Homo sapiens | CVCL_1564 | |
HCT 116 cells | Colon carcinoma | Homo sapiens | CVCL_0291 | ||
G13D (Human colorectal cancer cells) | |||||
DLD-1 cells | Colon adenocarcinoma | Homo sapiens | CVCL_0248 | ||
G12D (Human colorectal cancer cells) | |||||
CCD-18Co cells | Normal | Homo sapiens | CVCL_2379 | ||
In Vivo Model |
Animals (n = 7) were given 2.5% DSS in drinking water for 5 days and then no treatment for 14 days as one cycle; this process was repeated for three cycles. In the last cycle, 2% DSS water treated to each group and no treatment for 14 days. During the three DSS cycle, 3 mg/kg bromelain were injected daily intraperitoneally and colon and spleen tissues were harvested after three DSS cycle in 57 days to study polyp burden and to perform histological staining.
Click to Show/Hide
|
||||
Response regulation | Elevated miR-19b-3p, -130a-3p, -150-5p, -144-3p, -16-5p, -7a-5p, and -17-5p in bromelain-treated CaCO2cells compared to in DLD-1 cells potentially targeted ACSL-4 and resulted in suppression of ACSL-4. Overall, bromelain inhibits proliferation of Kras mutant Colorectal Cancer (CRC) effectively via ACSL-4. | ||||
Experiment 2 Reporting the Ferroptosis Target of This Regulator | [2] | ||||
Target for Ferroptosis | Driver | ||||
Responsed Disease | Osteosarcoma | ICD-11: 2B51 | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
Cell migration | |||||
Cell invasion | |||||
In Vitro Model |
143B cells | Osteosarcoma | Homo sapiens | CVCL_2270 | |
SW1353 cells | Bone chondrosarcoma | Homo sapiens | CVCL_0543 | ||
MG-63 cells | Osteosarcoma | Homo sapiens | CVCL_0426 | ||
SAOS-2 cells | Osteosarcoma | Homo sapiens | CVCL_0548 | ||
U2OS cells | Osteosarcoma | Homo sapiens | CVCL_0042 | ||
HOB (Human normal osteoblastic cells) | |||||
In Vivo Model |
The OS model of nude mice was constructed using the CDTX model. After transfection, the h143B cells were prepared into a single-cell suspension and subcutaneously injected into the left proximal tibia of 36 (3 mice per group) 4-weeks-old nude mice (1 x 107 cells per mouse).
Click to Show/Hide
|
||||
Response regulation | MiR-144-3p can induce the occurrence of ferroptosis by negatively regulating the expression of ZEB1, thereby inhibiting the proliferation, migration, and invasion of osteosarcoma (OS) cells. The overexpression of ZEB1 caused the lower expression level of ACSL4 and higher expression level of xCT and GPX4. | ||||
Phospholipid hydroperoxide glutathione peroxidase (GPX4) [Suppressor]
In total 1 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis Target of This Regulator | [2] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Osteosarcoma | ICD-11: 2B51 | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
Cell migration | |||||
Cell invasion | |||||
In Vitro Model |
143B cells | Osteosarcoma | Homo sapiens | CVCL_2270 | |
SW1353 cells | Bone chondrosarcoma | Homo sapiens | CVCL_0543 | ||
MG-63 cells | Osteosarcoma | Homo sapiens | CVCL_0426 | ||
SAOS-2 cells | Osteosarcoma | Homo sapiens | CVCL_0548 | ||
U2OS cells | Osteosarcoma | Homo sapiens | CVCL_0042 | ||
HOB (Human normal osteoblastic cells) | |||||
In Vivo Model |
The OS model of nude mice was constructed using the CDTX model. After transfection, the h143B cells were prepared into a single-cell suspension and subcutaneously injected into the left proximal tibia of 36 (3 mice per group) 4-weeks-old nude mice (1 x 107 cells per mouse).
Click to Show/Hide
|
||||
Response regulation | MiR-144-3p can induce the occurrence of ferroptosis by negatively regulating the expression of ZEB1, thereby inhibiting the proliferation, migration, and invasion of osteosarcoma (OS) cells. The overexpression of ZEB1 caused the lower expression level of ACSL4 and higher expression level of xCT and GPX4. | ||||
Colorectal cancer [ICD-11: 2B91]
In total 1 item(s) under this disease | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response | [1] | ||||
Target Regulator | hsa-miR-144-3p (miRNA) | miRNA | |||
Responsed Drug | Bromelain | Investigative | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
In Vitro Model |
NCI-H508 cells | Cecum adenocarcinoma | Homo sapiens | CVCL_1564 | |
HCT 116 cells | Colon carcinoma | Homo sapiens | CVCL_0291 | ||
G13D (Human colorectal cancer cells) | |||||
DLD-1 cells | Colon adenocarcinoma | Homo sapiens | CVCL_0248 | ||
G12D (Human colorectal cancer cells) | |||||
CCD-18Co cells | Normal | Homo sapiens | CVCL_2379 | ||
In Vivo Model |
Animals (n = 7) were given 2.5% DSS in drinking water for 5 days and then no treatment for 14 days as one cycle; this process was repeated for three cycles. In the last cycle, 2% DSS water treated to each group and no treatment for 14 days. During the three DSS cycle, 3 mg/kg bromelain were injected daily intraperitoneally and colon and spleen tissues were harvested after three DSS cycle in 57 days to study polyp burden and to perform histological staining.
Click to Show/Hide
|
||||
Response regulation | Elevated miR-19b-3p, -130a-3p, -150-5p, -144-3p, -16-5p, -7a-5p, and -17-5p in bromelain-treated CaCO2cells compared to in DLD-1 cells potentially targeted ACSL-4 and resulted in suppression of ACSL-4. Overall, bromelain inhibits proliferation of Kras mutant Colorectal Cancer (CRC) effectively via ACSL-4. | ||||
Osteosarcoma [ICD-11: 2B51]
In total 2 item(s) under this disease | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response | [2] | ||||
Target Regulator | hsa-miR-144-3p (miRNA) | miRNA | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
Cell migration | |||||
Cell invasion | |||||
In Vitro Model |
143B cells | Osteosarcoma | Homo sapiens | CVCL_2270 | |
SW1353 cells | Bone chondrosarcoma | Homo sapiens | CVCL_0543 | ||
MG-63 cells | Osteosarcoma | Homo sapiens | CVCL_0426 | ||
SAOS-2 cells | Osteosarcoma | Homo sapiens | CVCL_0548 | ||
U2OS cells | Osteosarcoma | Homo sapiens | CVCL_0042 | ||
HOB (Human normal osteoblastic cells) | |||||
In Vivo Model |
The OS model of nude mice was constructed using the CDTX model. After transfection, the h143B cells were prepared into a single-cell suspension and subcutaneously injected into the left proximal tibia of 36 (3 mice per group) 4-weeks-old nude mice (1 x 107 cells per mouse).
Click to Show/Hide
|
||||
Response regulation | MiR-144-3p can induce the occurrence of ferroptosis by negatively regulating the expression of ZEB1, thereby inhibiting the proliferation, migration, and invasion of osteosarcoma (OS) cells. The overexpression of ZEB1 caused the lower expression level of ACSL4 and higher expression level of xCT and GPX4. | ||||
Experiment 2 Reporting the Ferroptosis-centered Disease Response | [2] | ||||
Target Regulator | hsa-miR-144-3p (miRNA) | miRNA | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
Cell migration | |||||
Cell invasion | |||||
In Vitro Model |
143B cells | Osteosarcoma | Homo sapiens | CVCL_2270 | |
SW1353 cells | Bone chondrosarcoma | Homo sapiens | CVCL_0543 | ||
MG-63 cells | Osteosarcoma | Homo sapiens | CVCL_0426 | ||
SAOS-2 cells | Osteosarcoma | Homo sapiens | CVCL_0548 | ||
U2OS cells | Osteosarcoma | Homo sapiens | CVCL_0042 | ||
HOB (Human normal osteoblastic cells) | |||||
In Vivo Model |
The OS model of nude mice was constructed using the CDTX model. After transfection, the h143B cells were prepared into a single-cell suspension and subcutaneously injected into the left proximal tibia of 36 (3 mice per group) 4-weeks-old nude mice (1 x 107 cells per mouse).
Click to Show/Hide
|
||||
Response regulation | MiR-144-3p can induce the occurrence of ferroptosis by negatively regulating the expression of ZEB1, thereby inhibiting the proliferation, migration, and invasion of osteosarcoma (OS) cells. The overexpression of ZEB1 caused the lower expression level of ACSL4 and higher expression level of xCT and GPX4. | ||||
Bromelain
[Investigative]
In total 1 item(s) under this drug | |||||
Experiment 1 Reporting the Ferroptosis-centered Drug Response | [1] | ||||
Drug for Ferroptosis | Inducer | ||||
Response Target | Long-chain-fatty-acid--CoA ligase 4 (ACSL4) | Driver | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
In Vitro Model |
NCI-H508 cells | Cecum adenocarcinoma | Homo sapiens | CVCL_1564 | |
HCT 116 cells | Colon carcinoma | Homo sapiens | CVCL_0291 | ||
G13D (Human colorectal cancer cells) | |||||
DLD-1 cells | Colon adenocarcinoma | Homo sapiens | CVCL_0248 | ||
G12D (Human colorectal cancer cells) | |||||
CCD-18Co cells | Normal | Homo sapiens | CVCL_2379 | ||
In Vivo Model |
Animals (n = 7) were given 2.5% DSS in drinking water for 5 days and then no treatment for 14 days as one cycle; this process was repeated for three cycles. In the last cycle, 2% DSS water treated to each group and no treatment for 14 days. During the three DSS cycle, 3 mg/kg bromelain were injected daily intraperitoneally and colon and spleen tissues were harvested after three DSS cycle in 57 days to study polyp burden and to perform histological staining.
Click to Show/Hide
|
||||
Response regulation | Elevated miR-19b-3p, -130a-3p, -150-5p, -144-3p, -16-5p, -7a-5p, and -17-5p in bromelain-treated CaCO2cells compared to in DLD-1 cells potentially targeted ACSL-4 and resulted in suppression of ACSL-4. Overall, bromelain inhibits proliferation of Kras mutant Colorectal Cancer (CRC) effectively via ACSL-4. | ||||
References